Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Japan's First CRO CMIC On How ICH Affects Clinical Trials in Japan: An Interview with PharmAsia News (Part 2 of 2)

This article was originally published in PharmAsia News

Executive Summary

Established in 1992 as the first contract clinical trial research organization in Japan, CMIC is now one of the largest Japanese CROs and currently employs more than 2,500 employees. The company operates in Japan, the United States, South Korea, Taiwan, Singapore and China. CMIC Corporate Officer Asia Development Moriaki Akasaki sat down with PharmAsia News' Japan bureau to give his perspective on the how the International Conference on Harmonization Good Clinical Practices agreements will affect Japan and other Asian countries. Japan, for the first time is beginning to accept clinical data from China and Koreain accordance with the ICH Regional Harmonization Initiative.

You may also be interested in...



AstraZeneca's Research Grant System Expands in Japan For Academics Hungry For Industry Collaborations

TOKYO - Unlike the handful of global pharmaceutical competitors that closed up research operations in Japan a few years ago, AstraZeneca PLC has never had research facilities in Japan to close. But now, the company is trying to tap into academia to find useful technologies by awarding small grants to researchers, a program so successful that the company has launched similar efforts in South Korea and Russia

AstraZeneca's Research Grant System Expands in Japan For Academics Hungry For Industry Collaborations

TOKYO - Unlike the handful of global pharmaceutical competitors that closed up research operations in Japan a few years ago, AstraZeneca PLC has never had research facilities in Japan to close. But now, the company is trying to tap into academia to find useful technologies by awarding small grants to researchers, a program so successful that the company has launched similar efforts in South Korea and Russia

U.S. Private Equity Stake In CMIC Shows Rosy Outlook For Japan's Contract Research Market

TOKYO - U.S. private equity firm Taiyo Pacific Partners secured a 5 percent stake in CMIC, Japan's largest CRO, highlighting the CRO market growth potential in Japan, despite increased focus on R&D outsourcing to China and India

Related Content

UsernamePublicRestriction

Register

LL1134531

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel